---
title: A Study of Evacetrapib and Digoxin in Healthy Participants
nct_id: NCT01897493
overall_status: COMPLETED
phase: PHASE1
sponsor: Eli Lilly and Company
study_type: INTERVENTIONAL
primary_condition: Healthy Volunteers
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01897493.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01897493"
ct_last_update_post_date: 2018-10-09
last_seen_at: "2026-05-12T06:39:02.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of Evacetrapib and Digoxin in Healthy Participants

**Official Title:** Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects

**NCT ID:** [NCT01897493](https://clinicaltrials.gov/study/NCT01897493)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 16
- **Lead Sponsor:** Eli Lilly and Company
- **Conditions:** Healthy Volunteers
- **Start Date:** 2013-07
- **Completion Date:** 2013-09
- **CT.gov Last Update:** 2018-10-09

## Brief Summary

The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Overtly healthy males and females (of non-childbearing potential)
* Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2)
* Normal renal function

Exclusion Criteria:

* Participants who currently smoke or use tobacco or nicotine products
```

## Arms

- **Digoxin** (ACTIVE_COMPARATOR) — 0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
- **Evacetrapib + Digoxin** (EXPERIMENTAL) — 130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15

## Interventions

- **Evacetrapib** (DRUG) — Administered orally
- **Digoxin** (DRUG) — Administered orally

## Primary Outcomes

- **Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Digoxin** _(time frame: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin)_
- **PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of Digoxin** _(time frame: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin)_
- **PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin** _(time frame: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin)_

## Secondary Outcomes

- **Renal Clearance (CLr) of Digoxin** _(time frame: Periods 1 and 2: digoxin predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after administration of digoxin)_

## Locations (1)

- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician.|dallas|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01897493.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01897493*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*